Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Thoratec to broaden circulatory support leadership with pump buy

This article was originally published in Clinica

Executive Summary

Thoratec has added to its portfolio of mechanical circulatory support products by purchasing catheter pump technology from Stockholm, Sweden-based Getinge for $8.5m in cash. Thoratec plans to use the technology in the development of a minimally-invasive acute cardiac axial flow pump. According to Thoratec’s president and CEO, Gary Burbach, there is an unmet need for fast and minimally-invasive acute cardiac support for haemodynamically unstable acute myocardial infarction, high-risk percutaneous coronary intervention and post-cardiotomy patients. “Given its potential ability to provide greater flow at a smaller size than other existing devices, we believe this technology offers the potential to be the basis for a breakthrough offering in this very significant market,” said Mr Burbach. Pleasanton, California-based Thoratec expects to incur incremental development costs linked to the deal of up to $3m in 2010.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT045331

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel